Beyond low-density lipoprotein cholesterol: why, who and when.
- Author:
Christopher Ngai Kin CHANG
1
;
Choon How HOW
;
Subramaniam TAVINTHARAN
Author Information
1. SingHealth Polyclinics - Sengkang, 2 Sengkang Square, #01-06, Sengkang Community Hub, Singapore. christopher.chang.n.k@singhealth.com.sg
- Publication Type:Journal Article
- MeSH:
Coronary Disease;
prevention & control;
Drug Therapy, Combination;
Exercise;
Fenofibrate;
administration & dosage;
Humans;
Hypertriglyceridemia;
drug therapy;
therapy;
Hypoalphalipoproteinemias;
drug therapy;
therapy;
Hypolipidemic Agents;
administration & dosage;
Life Style;
Male;
Middle Aged;
Simvastatin;
administration & dosage
- From:Singapore medical journal
2012;53(9):566-quiz 569
- CountrySingapore
- Language:English
-
Abstract:
Cardiovascular disease due to atherosclerosis is a leading cause of death around the world, including Singapore. Current treatment strategies primarily target low-density lipoprotein (LDL) cholesterol levels. Low levels of high-density lipoprotein (HDL) cholesterol and high triglyceride (TG) levels have been shown to increase the risk of coronary heart disease, but the clinical benefits of raising low HDL cholesterol have only been proven in a limited number of studies. This guide provides an approach on managing low HDL cholesterol levels in terms of lifestyle modifications and pharmacotherapy.
